Thus, since VEGF-C-induced lymphangiogenesis has been described to improve the response to PD-1/CTLA-4 therapies in glioblastoma, LECs are now regarded as important mediators in potentiating immunotherapy (21, 203). Here, VEGFC is linked to glioblastoma.